Sensorion Aktie [WKN DE: A14SVV / ISIN: FR0012596468]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Sensorion SA

12.07.19		Sensorion Receives FDA IND Approval for Arazasetron (SENS-401) (Businesswire)
01.07.19		Sensorion Announces an Oral Presentation at the 5th Congress of European ORL-Head & Neck Surgery in Brussels (Businesswire)
28.06.19		Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications (Businesswire)
12.06.19		Sensorion Announces a €20m Convertible Bond Issue Subscribed by Two Renowned Investors Invus and Sofinnova Partners (Businesswire)
03.06.19		Sensorion Announces Poster Presentation at the "Société Internationale d’Otoneurologie” Symposium (Businesswire)
29.05.19		Sensorion: Reporting of the General Assembly (Businesswire)
27.05.19		Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss (Businesswire)
17.05.19		Sensorion announces oral presentation at the European Histamine Research Society (Businesswire)
15.05.19		Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV) (Businesswire)
27.03.19		Sensorion Reports Its 2018 Annual Results; 75% of Patients Enrolled in the Sens-111 Clinical Trial (Businesswire)
11.03.19		Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management (Businesswire)
14.02.18		Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting (Businesswire)
24.01.18		Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting (Businesswire)
21.12.17		Sensorion Successfully Closes on a €1.6 Million Euro Placement with Cochlear (Businesswire)
20.12.17		Sensorion to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018 (Businesswire)
18.12.17		Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant Patients (Businesswire)
18.10.17		Sensorion Reports 2017 First-Half Results (Businesswire)
11.09.17		Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study (Businesswire)
22.08.17		Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients (Businesswire)
02.05.17		Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model (Businesswire)
14.03.17		Sensorion Reports Full Year 2016 Results in Line with Status of Clinical Development (Businesswire)
09.03.17		Sensorion Receives European Authorization to Initiate Phase II Clinical Trial of SENS-111 to Treat Acute Vertigo (Businesswire)
29.11.16		Sensorion to Initiate a Phase 2 Clinical Trial with SENS-111, its Drug Candidate for Acute Severe Vertigo (Businesswire)
24.11.16		Sensorion Receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss (Businesswire)
17.11.16		Sensorion Presents New Preclinical Results with SENS-401 in Acute Sensorineural Hearing Loss at Neuroscience 2016 (Businesswire)
17.10.16		Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe (Businesswire)
13.10.16		Sensorion: 2016 First-Half Results (Businesswire)
06.10.16		Sensorion Presented Data from the Caloric Test with SENS-111 at the EACPT Conference (Businesswire)
29.09.16		Sensorion Selects New Drug Candidate, SENS-401, to Treat Vestibular and Auditory Disorders Associated with Inner Ear Lesions (Businesswire)
21.09.16		Sensorion: Initial Results of Phase 1b Clinical Study on SENS-111 presented at the AAO-HNSF Annual Meeting in San Diego (Businesswire)
19.09.16		Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress (Businesswire)
07.09.16		Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK (Businesswire)
07.09.16		Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK (Businesswire)
01.09.16		Sensorion to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (Businesswire)
01.09.16		Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo (Businesswire)
01.09.16		Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo (Businesswire)
17.08.16		Sensorion Strengthens Its Financial Structure with the Exercise of the Second Tranche of Its Financing Agreement (Businesswire)
12.05.16		Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting (Businesswire)
17.03.16		Sensorion Reports 2015 Annual Results in line with the Company’s Development (Businesswire)
22.02.16		Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting (Businesswire)
22.02.16		Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting (Businesswire)
11.02.16		Sensorion Receives French Tech Pass Certification (Businesswire)
11.02.16		Sensorion Receives French Tech Pass Certification (Businesswire)
08.02.16		Sensorion Provides 2016 Financial Calendar (Businesswire)
06.01.16		Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 (Businesswire)
19.11.15		Sensorion: Positive Results Obtained in Phase 1b of the Clinical Study on SENS-111 and Setting up of Additional Funding (Businesswire)
20.10.15		Sensorion Has Presented an Abstract on Recovering Hearing Loss at the Neuroscience 2015 Annual Meeting in Chicago (Businesswire)
20.07.15		Sensorion Successfully Closes an €8 Million International Private Placement to Accelerate Its Development Strategy (Businesswire)
04.06.15		Sensorion Announces Positive Results from a Preclinical Trial on Recovering Hearing Following Acoustic Trauma (Businesswire)
23.04.15		Sensorion Successfully Completes the First Part of the Clinical Trial on SENS-111, Which Aims to Treat Severe Bouts of Vertigo (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin Kurs Prognose: Absturz auf 90.000 US-Dollar bereits diese Woche?

EQS-CMS: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Release of a capital market information

Trump stellt erneut US-Rolle bei Vereinten Nationen infrage

ams-OSRAM-Aktie schächelt: ams-OSRAM erhält EU-Freigabe für staatliche Förderung aus Österreich

Investieren in die Zukunft: Diese 5 Quantencomputing-Aktien sind vielversprechend

Bundestagswahl in Deutschland: Union laut Hochrechnungen klar vorn, FDP scheitert an Fünf-Prozent-Hürde - SPD verliert deutlich

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.02.2025 00:28
Kaufwert:	EUR
	Hinzufügen Speichern